Online citations, reference lists, and bibliographies.
← Back to Search

Nasal Drug Delivery--possibilities, Problems And Solutions.

L. Illum
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper discusses the problems associated with nasal drug delivery and how it is possible, sometimes by means of quite simple concepts, to improve transport across the nasal membrane. In this way it is feasible to deliver efficiently challenging drugs such as small polar molecules, peptides and proteins and even the large proteins and polysaccharides used in vaccines or DNA plasmids exploited for DNA vaccines. The transport of drugs from the nasal cavity directly to the brain is also described and examples of studies in man, where this has been shown to be feasible, are discussed. Recent results from Phase I/II studies in man with a novel nasal chitosan vaccine delivery system are also described. Finally, the author's thoughts about the future for nasal drug delivery are also depicted.
This paper references
10.1023/A:1007542618378
Transfer of Dopamine in the Olfactory Pathway Following Nasal Administration in Mice
M. Dahlin (2004)
10.1016/0006-3223(95)00180-8
Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans
R. Pietrowsky (1996)
10.1002/JPS.2600770104
Mechanisms of corneal drug penetration. II: Ultrastructural analysis of potential pathways for drug movement.
G. Grass (1988)
10.1016/S0306-4530(96)00012-1
A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin
R. Pietrowsky (1996)
10.1016/S0378-5173(99)00030-7
Effect of chitosan on epithelial permeability and structure.
V. Dodane (1999)
10.1002/JPS.2600751113
Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin.
A. Harris (1986)
10.1210/JCEM.86.3.7298
The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans.
H. Fehm (2001)
10.1016/0006-291X(85)91224-0
Hydrolysis of leucine enkephalin in the nasal cavity of the rat--a possible factor in the low bioavailability of nasally administered peptides.
A. Hussain (1985)
10.1016/S0306-4530(99)00027-X
Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans
B. Perras (1999)
Macromolecular permeability of the tight junction of the human nasal mucosa.
M. Inagaki (1985)
10.1016/0378-5173(87)90216-X
Bioadhesive microspheres as a potential nasal drug delivery system
L. Illum (1987)
10.1124/JPET.301.1.391
Intranasal delivery of morphine.
L. Illum (2002)
Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue
L. Illum (2000)
10.1159/000054460
Brain Potentials and Attention after Acute and Subchronic Intranasal Administration of ACTH 4–10 and Desacetyl-α-MSH in Humans
R. Smolnik (1999)
10.1038/7385
Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
K. Roy (1999)
10.1023/A:1018967116988
Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)
P. Artursson (2004)
10.1016/S0024-3205(97)00149-5
The first attempt at radioisotopic evaluation of the integrity of the nose-brain barrier.
S. Okuyama (1997)
10.1016/S0264-410X(00)00063-3
Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.
F. Cano (2000)
10.1023/A:1011929016601
Chitosan and its use as a pharmaceutical excipient.
L. Illum (1998)
10.1016/S0264-410X(00)00055-4
Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).
K. Matsuo (2000)
10.1016/0024-3205(86)90150-5
Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases.
S. D. Kashi (1986)
10.1056/NEJM199805143382002
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
R. Belshe (1998)
BIOADHESIVE FORMULATIONS FOR NASAL PEPTIDE DELIVERY
L. Illum (1999)
10.1016/S0014-2999(00)00540-9
Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology?
H. Fehm (2000)
10.1016/S0378-5173(98)00367-6
Evaluation of the clearance characteristics of bioadhesive systems in humans.
R. Soane (1999)
10.1016/S0264-410X(02)00662-X
Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice.
M. Iqbal (2003)
10.1615/CRITREVTHERDRUGCARRIERSYST.V17.I3.10
New approaches to antigen delivery.
D. Fitzgerald (2000)
10.1016/S0169-409X(01)00171-5
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
10.1016/S0928-0987(00)00087-7
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
10.2337/DIABETES.48.3.557
Central nervous system effects of intranasally administered insulin during euglycemia in men.
W. Kern (1999)
10.1046/j.1468-2982.1997.1704541.x
Safety, Tolerability, and Pharmacokinetics of Sumatriptan in Healthy Subjects Following Ascending Single Intranasal Doses and Multiple Intranasal Doses
K. Moore (1997)
10.1097/00004714-199902000-00007
Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin.
B. Perras (1999)
10.1159/000054694
Improving Influence of Insulin on Cognitive Functions in Humans
W. Kern (2001)
10.1016/S0885-3924(02)00522-5
Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer.
H. Pavis (2002)
10.1016/S0895-7061(98)00095-8
Intranasal angiotensin II directly influences central nervous regulation of blood pressure.
I. Derad (1998)
10.1002/JPS.2600760709
Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity.
C. Mcmartin (1987)
10.1016/0378-5173(94)90439-1
Intranasal permeation of thyrotropin-releasing hormone: in vitro study of permeation and enzymatic degradation
L. Jørgensen (1994)
10.4049/jimmunol.165.9.4778
Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues
F. V. van Ginkel (2000)
10.1124/JPET.301.1.1
Pharmacology and toxicology of astrocyte-neuron glutamate transport and cycling.
U. Sonnewald (2002)
Enzymatic barriers to peptide and protein absorption.
V. Lee (1988)
10.1083/JCB.101.6.2124
Occluding junction structure-function relationships in a cultured epithelial monolayer
J. Madara (1985)



This paper is referenced by
10.1016/S1359-6446(02)02529-1
Nasal drug delivery: new developments and strategies.
L. Illum (2002)
10.3109/02652048.2011.630106
Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan
Chandrakant Pardeshi (2012)
10.1016/j.nut.2009.08.001
Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action.
R. Henkin (2010)
10.1517/17425247.2.2.281
Advances in nasal drug delivery through tight junction technology
P. H. Johnson (2005)
10.2165/00137696-200503030-00001
Thiomers: The Next Generation of Mucoadhesive Polymers
Andreas Bernkop-Schn rch (2005)
10.1080/03639040600712953
Transport Characteristics of a Beta Sheet Breaker Peptide Across Excised Bovine Nasal Mucosa
A. Greimel (2007)
10.1016/J.IJPHARM.2007.03.041
Pharmacokinetics of Gastrodin in rat plasma and CSF after i.n. and i.v.
Q. Wang (2007)
10.1007/12_2011_109
Chitosan and Thiolated Chitosan
Federica Sarti (2011)
10.1201/B15626-4
Design Challenges and Considerations for Nanomedical Ingress and Egress
Frank Boehm (2013)
10.1002/9780470571224.PSE521
Routes of Delivery for Biological Drug Products
D. Irvine (2013)
10.1002/jps.24022
Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure.
John D. Hoekman (2014)
10.1211/0022357023646
Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue
K. Koushik (2004)
Formulation and Development of In-Situ Nasal Gel of NH Liposome based drug delivery system for brain targeting through intranasal route 147 8 FORMULATION AND DEVELOPMENT OF THERMOREVERSIBLE IN-SITU NASAL GEL OF NARATRIPTAN HYDROCHLORIDE
(2015)
10.1007/s40005-016-0233-4
Quantitative evaluation of mucoadhesive polymers to compare the mucoadhesion
Cho-A Lee (2016)
10.1080/03639045.2017.1402918
Development of zolmitriptan transfersomes by Box–Behnken design for nasal delivery: in vitro and in vivo evaluation
Shravan Kumar Pitta (2018)
10.1201/B18096-3
Emerging Trends in Delivery of Novel Vaccine Formulations
Trinh Vo (2015)
10.1016/j.drudis.2014.06.004
Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively.
B. Pavan (2014)
10.1016/j.suponc.2011.07.004
Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
M. Fallon (2011)
10.1111/jphp.12043
Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel
Xi Chen (2013)
10.1111/j.2042-7158.2011.01381.x
The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co‐administered with bioadhesive polymers and an AT1002 antagonist, AT1001
Keon-Hyoung Song (2012)
10.1016/j.xphs.2019.03.006
The Hypotonic Environmental Changes Affect Liposomal Formulations for Nose-to-Brain Targeted Drug Delivery.
I. Wu (2019)
10.1111/jvim.15627
Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi‐center randomized parallel group clinical study
M. Charalambous (2019)
10.36348/sjmps.2020.v06i01.014
Formulation Optimization, Permeation Kinetic and Release Mechanism Study of In-Situ Nasal Gel Containing Ondansetron
P. De (2020)
10.1016/j.biomaterials.2013.02.003
Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Zhongyang Liu (2013)
10.3109/10837450903013568
Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design
J. Varshosaz (2010)
10.1517/14712598.3.3.519
Nasal drug delivery
Colin Diekens (2003)
A Review on Intranasal Drug Delivery System
Pagar Swati Appasaheb (2013)
Effects of novel chloroquine formulation on blood glucose concentration, renal and cardiovascular function in experimental animal paradigms.
P. Murambiwa (2011)
Development of osmotically active liposomes for nose-to-brain drug delivery
I. Wu (2019)
10.1631/jzus.B1000121
Enhancing effect of natural borneol on the absorption of geniposide in rat via intranasal administration
Y. Lu (2010)
10.1080/10611860600992157
Non-systemic delivery of topical brimonidine to the brain: A neuro-ocular tissue distribution study
S. Tamilvanan (2006)
10.1016/J.EJPS.2006.11.018
Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device.
S. Charlton (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar